Individualized therapy for metastatic colorectal cancer

A. Silvestri; E. Pin; A. Huijbers; R. Pellicani; E. M. Parasido; M. Pierobon; E. Petricoin; L. Liotta; C. Belluco

doi:10.1111/joim.12070

Individualized therapy for metastatic colorectal cancer

A. Silvestri, E. Pin, A. Huijbers, R. Pellicani, E. M. Parasido, M. Pierobon, E. Petricoin, L. Liotta, C. Belluco

Centro di Riferimento Oncologico

Research output: Contribution to journal › Article › peer-review

Abstract

Systemic therapeutic efficacy is central to determining the outcome of patients with metastatic colorectal cancer (CRC). In these patients, there is a critical need for predictive biomarkers to optimize efficacy whilst minimizing toxicity. The integration of a new generation of molecularly targeted drugs into the treatment of CRC, coupled with the development of sophisticated technologies for individual tumours as well as patient molecular profiling, underlines the potential for personalized medicine. In this review, we focus on the latest progress made within the genomic and proteomic fields, concerning predictive biomarkers for individualized therapy in metastatic CRC.

Original language	English
Pages (from-to)	1-24
Number of pages	24
Journal	Journal of Internal Medicine
Volume	274
Issue number	1
DOIs	https://doi.org/10.1111/joim.12070
Publication status	Published - Jul 2013

Keywords

Colorectal cancer
Genomic profiling
Individualized therapy
Predictive biomarkers
Proteomic profiling

ASJC Scopus subject areas

Internal Medicine

Access to Document

10.1111/joim.12070

Cite this

@article{e2bc88d0c1594226a762db6bd2d48c6d,

title = "Individualized therapy for metastatic colorectal cancer",

abstract = "Systemic therapeutic efficacy is central to determining the outcome of patients with metastatic colorectal cancer (CRC). In these patients, there is a critical need for predictive biomarkers to optimize efficacy whilst minimizing toxicity. The integration of a new generation of molecularly targeted drugs into the treatment of CRC, coupled with the development of sophisticated technologies for individual tumours as well as patient molecular profiling, underlines the potential for personalized medicine. In this review, we focus on the latest progress made within the genomic and proteomic fields, concerning predictive biomarkers for individualized therapy in metastatic CRC.",

keywords = "Colorectal cancer, Genomic profiling, Individualized therapy, Predictive biomarkers, Proteomic profiling",

author = "A. Silvestri and E. Pin and A. Huijbers and R. Pellicani and Parasido, {E. M.} and M. Pierobon and E. Petricoin and L. Liotta and C. Belluco",

year = "2013",

month = jul,

doi = "10.1111/joim.12070",

language = "English",

volume = "274",

pages = "1--24",

journal = "Journal of Internal Medicine",

issn = "0954-6820",

publisher = "Wiley-Blackwell",

number = "1",

}

TY - JOUR

T1 - Individualized therapy for metastatic colorectal cancer

AU - Silvestri, A.

AU - Pin, E.

AU - Huijbers, A.

AU - Pellicani, R.

AU - Parasido, E. M.

AU - Pierobon, M.

AU - Petricoin, E.

AU - Liotta, L.

AU - Belluco, C.

PY - 2013/7

Y1 - 2013/7

N2 - Systemic therapeutic efficacy is central to determining the outcome of patients with metastatic colorectal cancer (CRC). In these patients, there is a critical need for predictive biomarkers to optimize efficacy whilst minimizing toxicity. The integration of a new generation of molecularly targeted drugs into the treatment of CRC, coupled with the development of sophisticated technologies for individual tumours as well as patient molecular profiling, underlines the potential for personalized medicine. In this review, we focus on the latest progress made within the genomic and proteomic fields, concerning predictive biomarkers for individualized therapy in metastatic CRC.

AB - Systemic therapeutic efficacy is central to determining the outcome of patients with metastatic colorectal cancer (CRC). In these patients, there is a critical need for predictive biomarkers to optimize efficacy whilst minimizing toxicity. The integration of a new generation of molecularly targeted drugs into the treatment of CRC, coupled with the development of sophisticated technologies for individual tumours as well as patient molecular profiling, underlines the potential for personalized medicine. In this review, we focus on the latest progress made within the genomic and proteomic fields, concerning predictive biomarkers for individualized therapy in metastatic CRC.

KW - Colorectal cancer

KW - Genomic profiling

KW - Individualized therapy

KW - Predictive biomarkers

KW - Proteomic profiling

UR - http://www.scopus.com/inward/record.url?scp=84879104939&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84879104939&partnerID=8YFLogxK

U2 - 10.1111/joim.12070

DO - 10.1111/joim.12070

M3 - Article

C2 - 23527888

AN - SCOPUS:84879104939

SN - 0954-6820

VL - 274

SP - 1

EP - 24

JO - Journal of Internal Medicine

JF - Journal of Internal Medicine

IS - 1

ER -

Individualized therapy for metastatic colorectal cancer

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this